Sudeep Pharma IPO Launch: Key Details Inside
Sudeep Pharma is gearing up for its initial public offering (IPO) set to open on November 21 and close on November 25, 2025. The company aims to raise approximately Rs 895 crore through this issue, which consists of a fresh issue worth Rs 95 crore and an offer for sale (OFS) of 1,34,90,726 equity shares, each having a face value of Rs 1.
The price band for the IPO is set between Rs 563 to Rs 593 per share. The offering structure allocates 50% for qualified institutional buyers (QIBs), 35% for retail investors, and 15% for high-net-worth individuals. This tiered allocation ensures that various investor classes can participate in the offering.
Sudeep Pharma’s shares are expected to be listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on November 28, 2025, with the allotment process scheduled for November 26. This timeline creates a sense of urgency for potential investors looking to seize this opportunity.
In terms of financial performance, Sudeep Pharma reported a revenue of Rs 511.33 crore for FY25, reflecting growth from Rs 465.38 crore in FY24. Additionally, the net profit saw a slight increase to Rs 138.69 crore in FY25 from Rs 133.15 crore the previous year. These positive financial indicators make the IPO appealing, especially for those with a long-term investment perspective.
The company specializes in manufacturing pharmaceutical excipients, which are essential components that aid in the delivery of drugs. This IPO marks an important step for Sudeep Pharma as it ventures into the public market, with a portion of the proceeds allocated for acquiring machinery for its production line at the Nandesari facility. The remaining funds will be directed towards general corporate purposes, enhancing overall operational capacity.
Investors should note that the minimum application for the IPO is set at 25 shares per lot, making it accessible for retail participants. The involvement of notable financial institutions, such as ICICI Securities and IIFL Capital Services as book-running lead managers, adds credibility to this offering. Overall, Sudeep Pharma's IPO presents an intriguing opportunity for investors in the growing pharmaceutical sector.
